Cerebral Palsy Market by Product and Geography - Forecast and Analysis 2021-2025

***1. Executive Summary                           

                **1.1 Market Overview

                                *Exhibit 01:  Key Finding 1

                                *Exhibit 02:  Key Finding 2

                                *Exhibit 03:  Key Finding 3

                                *Exhibit 04:  Key Finding 5

                                *Exhibit 05:  Key Finding 6

                                *Exhibit 06:  Key Finding 7

                                *Exhibit 07:  Key Finding 8

***2. Market Landscape                             

                **2.1 Market ecosystem             

                                *2.1.1 Parent Market

                                *Exhibit 08:  Parent market

                                *Exhibit 09:  Market characteristics

                **2.2 Value chain analysis           

                                *Exhibit 10: Value chain analysis: Pharmaceuticals

                                *2.2.1 Research and development (R&D) and drug discovery

                                *2.2.2 Integration and product development

                                *2.2.3 Manufacturing

                                *2.2.4 Outbound logistics

                                *2.2.5 Marketing and sales

                                *2.2.6 Support services

                                *2.2.7 Innovation

***3. Market Sizing                       

                **3.1 Market definition

                                *Exhibit 11:  Offerings of vendors included in the market definition

                **3.2 Market segment analysis 

                                *Exhibit 12:  Market segments

                **3.3 Market size 2020 

                **3.4 Market outlook: Forecast for 2020 - 2025 

                                *3.4.1 Estimating growth rates for emerging and high-growth markets

                                *3.4.2 Estimating growth rates for mature markets

                                *Exhibit 13:  Global - Market size and forecast 2020 - 2025 ($ million)

                                *Exhibit 14:  Global market: Year-over-year growth 2020 - 2025 (%)

***4. Five Forces Analysis                          

                **4.1 Five Forces Summary        

                                *Exhibit 15:  Five forces analysis 2020 & 2025

                **4.2 Bargaining power of buyers           

                                *Exhibit 16: Bargaining power of buyers

                **4.3 Bargaining power of suppliers       

                                *Exhibit 17: Bargaining power of suppliers

                **4.4 Threat of new entrants    

                                *Exhibit 18: Threat of new entrants

                **4.5 Threat of substitutes         

                                *Exhibit 19: Threat of substitutes

                **4.6 Threat of rivalry   

                                *Exhibit 20: Threat of rivalry

                **4.7 Market condition

                                *Exhibit 21:  Market condition - Five forces 2020

***5 Market Segmentation by Product                

                **5.1 Market segments

                                *Exhibit 22:  Product - Market share 2020-2025 (%)

                **5.2 Comparison by Product    

                                *Exhibit 23:  Comparison by Product

                **5.3 Anticonvulsant drugs - Market size and forecast 2020-2025               

                                *Exhibit 24:  Anticonvulsant drugs - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 25:  Anticonvulsant drugs - Year-over-year growth 2020-2025 (%)

                **5.4 Antispastic drugs - Market size and forecast 2020-2025       

                                *Exhibit 26:  Antispastic drugs - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 27:  Antispastic drugs - Year-over-year growth 2020-2025 (%)

                **5.5 Anticholinergic drugs - Market size and forecast 2020-2025               

                                *Exhibit 28:  Anticholinergic drugs - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 29:  Anticholinergic drugs - Year-over-year growth 2020-2025 (%)

                **5.6 NSAIDs - Market size and forecast 2020-2025          

                                *Exhibit 30:  NSAIDs - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 31:  NSAIDs - Year-over-year growth 2020-2025 (%)

                **5.7 Antidepressants and others - Market size and forecast 2020-2025  

                                *Exhibit 32:  Antidepressants and others - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 33:  Antidepressants and others - Year-over-year growth 2020-2025 (%)

                **5.8 Market opportunity by Product    

                                *Exhibit 34:  Market opportunity by Product

***6. Customer landscape                         

                **6.1 Overview

                                *Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

                                *Exhibit 35: ?Customer landscape?

***7. Geographic Landscape                     

                **7.1 Geographic segmentation

                                *Exhibit 36:  Market share by geography 2020-2025 (%)

                **7.2 Geographic comparison   

                                *Exhibit 37: Geographic comparison

                **7.3 North America - Market size and forecast 2020-2025           

                                *Exhibit 38:  North America - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 39:  North America - Year-over-year growth 2020-2025 (%)

                **7.4 Asia - Market size and forecast 2020-2025

                                *Exhibit 40:   Asia - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 41:  Asia - Year-over-year growth 2020-2025 (%)

                **7.5 Europe - Market size and forecast 2020-2025          

                                *Exhibit 42:   Europe - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 43:  Europe - Year-over-year growth 2020-2025 (%)

                **7.6 ROW - Market size and forecast 2020-2025              

                                *Exhibit 44:   ROW - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 45:  ROW - Year-over-year growth 2020-2025 (%)

                **7.7 Key leading countries        

                                *Exhibit 46:  Key leading countries

                **7.8 Market opportunity by geography

                                *Exhibit 47: Market opportunity by geography

***8. Drivers, Challenges, and Trends                   

                **8.1 Market drivers     

                                *8.1.1 Rising incidence of cerebral palsy

                                *8.1.2 Increasing awareness about cerebral palsy

                                *8.1.3 High patient dependence on medications for cerebral palsy

                **8.2 Market challenges              

                                *8.2.1 Complex and multifactorial etiology

                                *8.2.2 Absence of a curative approach for cerebral palsy

                                *8.2.3 Disabilities and health problems associated with cerebral palsy

                                *Exhibit 48:  Impact of drivers and challenges

                **8.3 Market trends      

                                *8.3.1 Availability of advanced therapeutic modalities for cerebral palsy

                                *8.3.2 Increasing cerebral palsy research

                                *8.3.3 Increasing funding by governments for patients with cerebral palsy

***9. Vendor Landscape                             

                **9.1 Overview

                                *Exhibit 49: Vendor landscape

                                *The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025. 

                **9.2 Landscape disruption        

                                *Exhibit 50: ?Landscape disruption?

                                *Exhibit 51: Industry risks

                **9.3 Competitive landscape     

***10. Vendor Analysis               

                **10.1 Vendors covered              

                                *Exhibit 52: Vendors covered

                **10.2 Market positioning of vendors    

                                *Exhibit 53: ?Market positioning of vendors?

                **10.3 Abbott Laboratories        

                                *Exhibit 54:  Abbott Laboratories  - Overview

                                *Exhibit 55:  Abbott Laboratories  - Business segments

                                *Exhibit 56:  Abbott Laboratories  - Key offerings

                                *Exhibit 57:  Abbott Laboratories  - Segment focus

                **10.4 AbbVie Inc.         

                                *Exhibit 58:  AbbVie Inc. - Overview

                                *Exhibit 59:  AbbVie Inc. - Business segments

                                *Exhibit 60:  AbbVie Inc. - Key offerings

                                *Exhibit 61:  AbbVie Inc. - Segment focus

                **10.5 Acorda Therapeutics Inc.

                                *Exhibit 62:  Acorda Therapeutics Inc. - Overview

                                *Exhibit 63:  Acorda Therapeutics Inc. - Business segments

                                *Exhibit 64:  Acorda Therapeutics Inc. - Key offerings

                                *Exhibit 65:  Acorda Therapeutics Inc. - Segment focus

                **10.6 Eli Lilly and Co.  

                                *Exhibit 66:  Eli Lilly and Co. - Overview

                                *Exhibit 67:  Eli Lilly and Co. - Business segments

                                *Exhibit 68:  Eli Lilly and Co. - Key offerings

                                *Exhibit 69:  Eli Lilly and Co. - Segment focus

                *10.7 F. Hoffmann-La Roche Ltd.

                               *Exhibit 70:  F. Hoffmann-La Roche Ltd. - Overview         

                               *Exhibit 71:  F. Hoffmann-La Roche Ltd. - Business segments      

                               *Exhibit 72:  F. Hoffmann-La Roche Ltd. - Key offerings  

                               *Exhibit 73:  F. Hoffmann-La Roche Ltd. - Segment focus

                **10.8 GlaxoSmithKline Plc         

                                *Exhibit 74:  GlaxoSmithKline Plc - Overview

                                *Exhibit 75:  GlaxoSmithKline Plc - Business segments

                                *Exhibit 76:  GlaxoSmithKline Plc - Key offerings

                                *Exhibit 77:  GlaxoSmithKline Plc - Segment focus

                **10.9 GW Pharmaceuticals Plc

                                *Exhibit 78:  GW Pharmaceuticals Plc - Overview

                                *Exhibit 79:  GW Pharmaceuticals Plc - Business segments

                                *Exhibit 80:  GW Pharmaceuticals Plc - Key offerings

                                *Exhibit 81:  GW Pharmaceuticals Plc - Segment focus

                **10.10 Johnson and Johnson Inc.           

                                *Exhibit 82:  Johnson and Johnson Inc.  - Overview

                                *Exhibit 83:  Johnson and Johnson Inc.  - Business segments

                                *Exhibit 84:  Johnson and Johnson Inc.  - Key offerings

                                *Exhibit 85:  Johnson and Johnson Inc.  - Segment focus

                **10.11 Medtronic Plc  

                                *Exhibit 86:  Medtronic Plc - Overview

                                *Exhibit 87:  Medtronic Plc - Business segments

                                *Exhibit 88:  Medtronic Plc - Key offerings

                                *Exhibit 89:  Medtronic Plc - Segment focus

                **10.12 Pfizer Inc.          

                                *Exhibit 90:  Pfizer Inc. - Overview

                                *Exhibit 91:  Pfizer Inc. - Business segments

                                *Exhibit 92:  Pfizer Inc. - Key offerings

                                *Exhibit 93:  Pfizer Inc. - Segment focus

***11. Appendix                            

                **11.1 Scope of the report         

                                *11.1.1 ????Market definition

                                *11.1.2 ????Objectives

                                *11.1.3 ????Notes and caveats

                **11.2 Currency conversion rates for US$            

                                *Exhibit 94: ?Currency conversion rates for US$?

                **11.3 Research Methodology 

                                *Exhibit 95: ?Research Methodology

                                *Exhibit 96: ??Validation techniques employed for market sizing?

                                *Exhibit 97: ??Information sources

                **11.4 List of abbreviations        

                                *Exhibit 98: List of abbreviations